Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
31
STAA Quote, Financials, Valuation and Earnings
Last price:
$23.70
Seasonality move
:
0.32%
Day range:
$23.51 - $23.97
52-week range:
$13.50 - $30.81
Dividend yield:
0%
P/E ratio:
49.73x
P/S ratio:
5.09x
P/B ratio:
3.30x
Volume:
264.7K
Avg. volume:
1.3M
1-year change:
-5.37%
Market cap:
$1.2B
Revenue:
$313.9M
EPS (TTM):
-$1.96
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
STAA
STAAR Surgical Co.
|
$89.4M | $0.28 | 54.33% | 39.51% | $26.56 |
|
COO
The Cooper Cos., Inc.
|
$1.1B | $1.11 | 6.12% | 98.42% | $90.50 |
|
KIDS
OrthoPediatrics Corp.
|
$62M | -$0.26 | 12.55% | -54.72% | $24.13 |
|
LUCY
Innovative Eyewear, Inc.
|
$1M | -$0.49 | 73.74% | -50.4% | $3.00 |
|
NXGL
NexGel, Inc.
|
$3.2M | -$0.08 | 6.54% | -22.68% | $6.00 |
|
PRCT
PROCEPT BioRobotics Corp.
|
$80.8M | -$0.42 | 37.32% | -7.78% | $50.73 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
STAA
STAAR Surgical Co.
|
$23.63 | $26.56 | $1.2B | 49.73x | $0.00 | 0% | 5.09x |
|
COO
The Cooper Cos., Inc.
|
$82.57 | $90.50 | $16.2B | 44.06x | $0.01 | 0% | 4.04x |
|
KIDS
OrthoPediatrics Corp.
|
$17.41 | $24.13 | $436.6M | -- | $0.00 | 0% | 1.79x |
|
LUCY
Innovative Eyewear, Inc.
|
$1.36 | $3.00 | $7.3M | -- | $0.00 | 0% | 1.85x |
|
NXGL
NexGel, Inc.
|
$1.59 | $6.00 | $12.9M | -- | $0.00 | 0% | 1.04x |
|
PRCT
PROCEPT BioRobotics Corp.
|
$32.88 | $50.73 | $1.8B | -- | $0.00 | 0% | 6.03x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
STAA
STAAR Surgical Co.
|
9.96% | 0.980 | 2.95% | 4.10x |
|
COO
The Cooper Cos., Inc.
|
25.25% | 0.349 | 20.32% | 0.89x |
|
KIDS
OrthoPediatrics Corp.
|
22.39% | -0.034 | 21.68% | 3.39x |
|
LUCY
Innovative Eyewear, Inc.
|
1.01% | 5.608 | 1.04% | 9.17x |
|
NXGL
NexGel, Inc.
|
38.1% | -0.508 | 15.76% | 0.82x |
|
PRCT
PROCEPT BioRobotics Corp.
|
17.19% | 1.043 | 3.96% | 7.07x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
STAA
STAAR Surgical Co.
|
$76.6M | $44.5M | -23.38% | -25.83% | 46.96% | $1.8M |
|
COO
The Cooper Cos., Inc.
|
$601M | $140.4M | 3.45% | 4.56% | 13.18% | $149.9M |
|
KIDS
OrthoPediatrics Corp.
|
$40M | -$4.9M | -10.3% | -12.83% | -7.95% | -$3.4M |
|
LUCY
Innovative Eyewear, Inc.
|
$244.8K | -$1.9M | -79.57% | -80% | -287.5% | -$1.5M |
|
NXGL
NexGel, Inc.
|
$1.2M | -$725K | -33.25% | -51.15% | -24.71% | -$793K |
|
PRCT
PROCEPT BioRobotics Corp.
|
$52.4M | -$23.2M | -19.24% | -23.51% | -27.83% | -$9.5M |
STAAR Surgical Co. vs. Competitors
-
Which has Higher Returns STAA or COO?
The Cooper Cos., Inc. has a net margin of 9.38% compared to STAAR Surgical Co.'s net margin of 7.94%. STAAR Surgical Co.'s return on equity of -25.83% beat The Cooper Cos., Inc.'s return on equity of 4.56%.
Company Gross Margin Earnings Per Share Invested Capital STAASTAAR Surgical Co.80.89% $0.18 $392.9M COOThe Cooper Cos., Inc.56.42% $0.43 $11B -
What do Analysts Say About STAA or COO?
STAAR Surgical Co. has a consensus price target of $26.56, signalling upside risk potential of 12.41%. On the other hand The Cooper Cos., Inc. has an analysts' consensus of $90.50 which suggests that it could grow by 9.6%. Given that STAAR Surgical Co. has higher upside potential than The Cooper Cos., Inc., analysts believe STAAR Surgical Co. is more attractive than The Cooper Cos., Inc..
Company Buy Ratings Hold Ratings Sell Ratings STAASTAAR Surgical Co.1 9 0 COOThe Cooper Cos., Inc.6 7 1 -
Is STAA or COO More Risky?
STAAR Surgical Co. has a beta of 1.008, which suggesting that the stock is 0.806% more volatile than S&P 500. In comparison The Cooper Cos., Inc. has a beta of 1.048, suggesting its more volatile than the S&P 500 by 4.779%.
-
Which is a Better Dividend Stock STAA or COO?
STAAR Surgical Co. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Cooper Cos., Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.01 per share. STAAR Surgical Co. pays -- of its earnings as a dividend. The Cooper Cos., Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios STAA or COO?
STAAR Surgical Co. quarterly revenues are $94.7M, which are smaller than The Cooper Cos., Inc. quarterly revenues of $1.1B. STAAR Surgical Co.'s net income of $8.9M is lower than The Cooper Cos., Inc.'s net income of $84.6M. Notably, STAAR Surgical Co.'s price-to-earnings ratio is 49.73x while The Cooper Cos., Inc.'s PE ratio is 44.06x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for STAAR Surgical Co. is 5.09x versus 4.04x for The Cooper Cos., Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income STAASTAAR Surgical Co.5.09x 49.73x $94.7M $8.9M COOThe Cooper Cos., Inc.4.04x 44.06x $1.1B $84.6M
-
Which has Higher Returns STAA or KIDS?
OrthoPediatrics Corp. has a net margin of 9.38% compared to STAAR Surgical Co.'s net margin of -19.22%. STAAR Surgical Co.'s return on equity of -25.83% beat OrthoPediatrics Corp.'s return on equity of -12.83%.
Company Gross Margin Earnings Per Share Invested Capital STAASTAAR Surgical Co.80.89% $0.18 $392.9M KIDSOrthoPediatrics Corp.65.27% -$0.50 $450.1M -
What do Analysts Say About STAA or KIDS?
STAAR Surgical Co. has a consensus price target of $26.56, signalling upside risk potential of 12.41%. On the other hand OrthoPediatrics Corp. has an analysts' consensus of $24.13 which suggests that it could grow by 38.57%. Given that OrthoPediatrics Corp. has higher upside potential than STAAR Surgical Co., analysts believe OrthoPediatrics Corp. is more attractive than STAAR Surgical Co..
Company Buy Ratings Hold Ratings Sell Ratings STAASTAAR Surgical Co.1 9 0 KIDSOrthoPediatrics Corp.4 1 0 -
Is STAA or KIDS More Risky?
STAAR Surgical Co. has a beta of 1.008, which suggesting that the stock is 0.806% more volatile than S&P 500. In comparison OrthoPediatrics Corp. has a beta of 1.062, suggesting its more volatile than the S&P 500 by 6.186%.
-
Which is a Better Dividend Stock STAA or KIDS?
STAAR Surgical Co. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OrthoPediatrics Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. STAAR Surgical Co. pays -- of its earnings as a dividend. OrthoPediatrics Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios STAA or KIDS?
STAAR Surgical Co. quarterly revenues are $94.7M, which are larger than OrthoPediatrics Corp. quarterly revenues of $61.3M. STAAR Surgical Co.'s net income of $8.9M is higher than OrthoPediatrics Corp.'s net income of -$11.8M. Notably, STAAR Surgical Co.'s price-to-earnings ratio is 49.73x while OrthoPediatrics Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for STAAR Surgical Co. is 5.09x versus 1.79x for OrthoPediatrics Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income STAASTAAR Surgical Co.5.09x 49.73x $94.7M $8.9M KIDSOrthoPediatrics Corp.1.79x -- $61.3M -$11.8M
-
Which has Higher Returns STAA or LUCY?
Innovative Eyewear, Inc. has a net margin of 9.38% compared to STAAR Surgical Co.'s net margin of -274.85%. STAAR Surgical Co.'s return on equity of -25.83% beat Innovative Eyewear, Inc.'s return on equity of -80%.
Company Gross Margin Earnings Per Share Invested Capital STAASTAAR Surgical Co.80.89% $0.18 $392.9M LUCYInnovative Eyewear, Inc.36.64% -$0.38 $10.4M -
What do Analysts Say About STAA or LUCY?
STAAR Surgical Co. has a consensus price target of $26.56, signalling upside risk potential of 12.41%. On the other hand Innovative Eyewear, Inc. has an analysts' consensus of $3.00 which suggests that it could grow by 120.59%. Given that Innovative Eyewear, Inc. has higher upside potential than STAAR Surgical Co., analysts believe Innovative Eyewear, Inc. is more attractive than STAAR Surgical Co..
Company Buy Ratings Hold Ratings Sell Ratings STAASTAAR Surgical Co.1 9 0 LUCYInnovative Eyewear, Inc.0 0 0 -
Is STAA or LUCY More Risky?
STAAR Surgical Co. has a beta of 1.008, which suggesting that the stock is 0.806% more volatile than S&P 500. In comparison Innovative Eyewear, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock STAA or LUCY?
STAAR Surgical Co. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innovative Eyewear, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. STAAR Surgical Co. pays -- of its earnings as a dividend. Innovative Eyewear, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios STAA or LUCY?
STAAR Surgical Co. quarterly revenues are $94.7M, which are larger than Innovative Eyewear, Inc. quarterly revenues of $668.1K. STAAR Surgical Co.'s net income of $8.9M is higher than Innovative Eyewear, Inc.'s net income of -$1.8M. Notably, STAAR Surgical Co.'s price-to-earnings ratio is 49.73x while Innovative Eyewear, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for STAAR Surgical Co. is 5.09x versus 1.85x for Innovative Eyewear, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income STAASTAAR Surgical Co.5.09x 49.73x $94.7M $8.9M LUCYInnovative Eyewear, Inc.1.85x -- $668.1K -$1.8M
-
Which has Higher Returns STAA or NXGL?
NexGel, Inc. has a net margin of 9.38% compared to STAAR Surgical Co.'s net margin of -22.05%. STAAR Surgical Co.'s return on equity of -25.83% beat NexGel, Inc.'s return on equity of -51.15%.
Company Gross Margin Earnings Per Share Invested Capital STAASTAAR Surgical Co.80.89% $0.18 $392.9M NXGLNexGel, Inc.40.93% -$0.08 $8.8M -
What do Analysts Say About STAA or NXGL?
STAAR Surgical Co. has a consensus price target of $26.56, signalling upside risk potential of 12.41%. On the other hand NexGel, Inc. has an analysts' consensus of $6.00 which suggests that it could grow by 277.36%. Given that NexGel, Inc. has higher upside potential than STAAR Surgical Co., analysts believe NexGel, Inc. is more attractive than STAAR Surgical Co..
Company Buy Ratings Hold Ratings Sell Ratings STAASTAAR Surgical Co.1 9 0 NXGLNexGel, Inc.0 0 0 -
Is STAA or NXGL More Risky?
STAAR Surgical Co. has a beta of 1.008, which suggesting that the stock is 0.806% more volatile than S&P 500. In comparison NexGel, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock STAA or NXGL?
STAAR Surgical Co. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NexGel, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. STAAR Surgical Co. pays -- of its earnings as a dividend. NexGel, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios STAA or NXGL?
STAAR Surgical Co. quarterly revenues are $94.7M, which are larger than NexGel, Inc. quarterly revenues of $2.9M. STAAR Surgical Co.'s net income of $8.9M is higher than NexGel, Inc.'s net income of -$647K. Notably, STAAR Surgical Co.'s price-to-earnings ratio is 49.73x while NexGel, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for STAAR Surgical Co. is 5.09x versus 1.04x for NexGel, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income STAASTAAR Surgical Co.5.09x 49.73x $94.7M $8.9M NXGLNexGel, Inc.1.04x -- $2.9M -$647K
-
Which has Higher Returns STAA or PRCT?
PROCEPT BioRobotics Corp. has a net margin of 9.38% compared to STAAR Surgical Co.'s net margin of -25.7%. STAAR Surgical Co.'s return on equity of -25.83% beat PROCEPT BioRobotics Corp.'s return on equity of -23.51%.
Company Gross Margin Earnings Per Share Invested Capital STAASTAAR Surgical Co.80.89% $0.18 $392.9M PRCTPROCEPT BioRobotics Corp.62.87% -$0.38 $459.2M -
What do Analysts Say About STAA or PRCT?
STAAR Surgical Co. has a consensus price target of $26.56, signalling upside risk potential of 12.41%. On the other hand PROCEPT BioRobotics Corp. has an analysts' consensus of $50.73 which suggests that it could grow by 54.28%. Given that PROCEPT BioRobotics Corp. has higher upside potential than STAAR Surgical Co., analysts believe PROCEPT BioRobotics Corp. is more attractive than STAAR Surgical Co..
Company Buy Ratings Hold Ratings Sell Ratings STAASTAAR Surgical Co.1 9 0 PRCTPROCEPT BioRobotics Corp.8 3 0 -
Is STAA or PRCT More Risky?
STAAR Surgical Co. has a beta of 1.008, which suggesting that the stock is 0.806% more volatile than S&P 500. In comparison PROCEPT BioRobotics Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock STAA or PRCT?
STAAR Surgical Co. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PROCEPT BioRobotics Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. STAAR Surgical Co. pays -- of its earnings as a dividend. PROCEPT BioRobotics Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios STAA or PRCT?
STAAR Surgical Co. quarterly revenues are $94.7M, which are larger than PROCEPT BioRobotics Corp. quarterly revenues of $83.3M. STAAR Surgical Co.'s net income of $8.9M is higher than PROCEPT BioRobotics Corp.'s net income of -$21.4M. Notably, STAAR Surgical Co.'s price-to-earnings ratio is 49.73x while PROCEPT BioRobotics Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for STAAR Surgical Co. is 5.09x versus 6.03x for PROCEPT BioRobotics Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income STAASTAAR Surgical Co.5.09x 49.73x $94.7M $8.9M PRCTPROCEPT BioRobotics Corp.6.03x -- $83.3M -$21.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
